A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

A new study published in the Journal of American Medical Association showed that individuals with autoimmune skin diseases ...

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

The International Medical Derm Summit 2025 highlighted China's dermatological advancements, fostering global collaboration ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

New study in Stem Cell Research & Therapy reveals biological pathways behind hair loss, potential new treatments.